BioTuesdays

Tag - PBLA

Panbela-Therapeutics

Maxim starts Panbela Therapeutics at buy; PT $8

Maxim Group launched coverage of Panbela Therapeutics (NASDAQ:PBLA) with a “buy” rating and $8 price target. The stock closed at $4.17 on March 9. The company’s polyamine metabolic inhibitor drug candidate, SBP...